Cite
HARVARD Citation
Sharma, M. et al. (n.d.). 401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. Journal for immunotherapy of cancer. p. A426. [Online].